The Accelerated Approval Risk: When Speed Costs You the Asset

← Back to All Insights

FDA's Accelerated Approval pathway promises faster patient access for serious conditions where surrogate endpoints predict clinical benefit. It also carries post-marketing confirmatory trial obligations that have ended more than one biotech. Understanding when accelerated approval is an asset versus when it becomes the trap that withdraws your drug from the market is critical diligence for any therapeutics investor.

The Aduhelm withdrawal, the Makena removal, and the prolonged confirmatory-trial obligations on Exondys 51 are not anomalies. They are predictable outcomes when companies treat accelerated approval as a finish line rather than a milestone.

How Accelerated Approval Actually Works

Subpart H (drugs) and Subpart E (biologics) authorize the FDA to approve products based on a surrogate endpoint reasonably likely to predict clinical benefit. The sponsor commits to confirmatory trials that verify the predicted benefit. If the confirmatory trial fails, FDA can withdraw the product. The pathway is not a regulatory shortcut—it is a deferred verification.

The Confirmatory Trial Time Bomb

The median time from accelerated approval to confirmatory trial completion is 4.6 years; many drugs operate under accelerated approval for 8-12 years. During that window, the sponsor must invest in expensive Phase 4 trials while also commercializing, building manufacturing scale, and competing with rivals who may follow with traditional approvals on stronger evidence. Investor diligence frequently ignores the confirmatory trial cost curve.

Withdrawal Risk Is Not Theoretical

Since 1992, FDA has withdrawn 16 accelerated approvals where confirmatory trials failed to verify benefit. That number jumped post-2020 as the agency adopted a more assertive withdrawal posture under the FDA Modernization Act 3.0 reforms. The 2023 Makena withdrawal—six years after the confirmatory trial read out negative—signaled that the agency will eventually act on confirmed-negative data.

Diligence Red Flags

Vantage's framework flags accelerated approval assets where: the surrogate endpoint has weak biological linkage to clinical outcome; the confirmatory trial is enrolling slowly relative to plan; the sponsor's runway is materially shorter than the confirmatory trial readout; or the comparator arm in the confirmatory trial is a moving target as standard of care evolves.

When Accelerated Approval Is the Right Strategy

For rare disease therapies with high unmet need, accelerated approval can be transformative—both for patients and the business. The biological linkage matters: in oncology with overall response rate as the surrogate, the linkage is strong. In neurodegeneration with biomarker endpoints, the linkage is contested. Match the pathway to the biology, not to the timeline pressure.

The Post-Approval Reality

Successful accelerated-approval programs treat the confirmatory trial as the highest-priority post-approval activity. They build dedicated trial operations, communicate confirmatory progress to FDA quarterly, and prepare alternative trials in parallel in case the primary endpoint underperforms. The pattern is not complex; what is rare is the discipline.

Accelerated approval is a powerful tool when matched to the right asset and operated with the right discipline. It is also one of the most expensive mistakes a therapeutics company can make when treated as a shortcut. For investors, the diligence question is not whether the pathway is available—it is whether the company has built the operational and financial foundation to survive the confirmatory trial window.